COMMUNIQUÉS West-GlobeNewswire

ICPO Foundation funded global “Radiopharmaceutical Trial Finder” developed by WARMTH and Ancora.ai

16/10/2024 - 13:00

This pioneering global trial finder tool powered by AI will be presented at the EANM Congress 2024 in Hamburg from Oct 20-22, 2024 October 16, 2024 – Wiesbaden, Germany and Zurich, Switzerland. Radiopharmaceuticals, a [...]

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

16/10/2024 - 13:00

SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy [...]

Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo

16/10/2024 - 13:00

Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgery NEW YORK, [...]

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

16/10/2024 - 13:00

CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a [...]

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16/10/2024 - 13:00

WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]

Hydreight Provides Corporate Update Reflecting Significant Growth

16/10/2024 - 13:00

Hydreight reported record Topline¹ Revenue of $10.46M in the first 6 months of 2024. Q2, 2024 GAAP revenue was $4.10 million an increase of 52% compared to Q2, 2023. Q2, 2024 Adjusted EBITDA¹ was $218K compared to ($ [...]

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

16/10/2024 - 13:00

Company to host a webinar on the detailed VALIANT results at 12:30 p.m. PT on Saturday, October 26 WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the [...]

Opthea Files Notice of Annual General Meeting

16/10/2024 - 13:00

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda [...]

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

16/10/2024 - 13:00

SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]

Tilray Announces Fall Craft Beer Lineup

16/10/2024 - 13:00

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company, is thrilled to announce a series of fall-themed product launches [...]

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

16/10/2024 - 13:00

Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in ﬁrst quarter of 2025 LOS [...]

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

16/10/2024 - 13:00

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by the FDA for NCP The Phase 2 trial is [...]

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

16/10/2024 - 12:50

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema ( [...]

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

16/10/2024 - 12:00

MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim [...]

Medigene to Present at Upcoming Scientific Conferences

16/10/2024 - 11:30

Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies [...]

Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication

16/10/2024 - 11:30

NG101 Significantly Reduced Incidence of Nausea by 40% and Frequency of Vomiting by 56% without Changing the Safety Profile of the GLP-1 Agonist WOBURN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Neurogastrx, Inc. today [...]

Cytosurge et Lexogen s’associent pour faire progresser le séquençage des cellules vivantes

16/10/2024 - 11:20

Collaboration pour permettre le séquençage des biopsies cellulaires ZURICH, Suisse et VIENNE, Autriche, 16 oct. 2024 (GLOBE NEWSWIRE) -- Cytosurge AG, un leader dans la manipulation des cellules uniques, et Lexogen, [...]

Trading by management and close relations of management

16/10/2024 - 09:58

Please see the attached PDF for details. Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation [...]

Ikerian Announces Series B Funding First close of USD 8M (CHF 6.73M) Led by Sanoptis with Commercial Agreement to Expand RetinAI Discovery in Europe

16/10/2024 - 09:00

First close Series B funding round raises USD 8M (CHF 6.73M) led by new investor, Sanoptis, with participation from existing investors the THINC Ventures arm of Topcon Healthcare, Inc, Zürcher Kantonalbank and Verve [...]